• We are a biotech company in
    infectious diseases with a
    first marketed product.

  • We are dedicated to
    innovation in antibody
    discovery and vaccine R&D.

  • Valneva covers the full
    value chain from bench
    to market.

Welcome to Valneva

Joining forces to create a European biotech leader in vaccines and antibodies


— August 8, 2014

Valneva significantly reduced its net loss and EBITDA in the first half
Download PR
Download Half Year Report
Download Analysts Presentation
View Webcast

— Stock information



—News, May 19, 2014

Valneva Announces the First Ever Marketing Approval in Europe for a vaccine produced in the EB66® Cell Line

 All News

— Financial calendar

 All dates

November 6, 2014
Q3 Results 

— Upcoming conferences and fairs

October 13 - 15, 2014
World Vaccine Congress Europe
Brussels, Belgium

Meet our Business Development team


European biotech company with worldwide presence.

Please update your browser...